We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-7.07%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$393M
AUM Growth
-$29.9M
Cap. Flow
+$15.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$5.71M
2
TELA icon
TELA Bio
TELA
+$4.05M
3
KROS icon
Keros Therapeutics
KROS
+$2.94M
4
BPMC
Blueprint Medicines
BPMC
+$2.56M
5
BCAX
Bicara Therapeutics
BCAX
+$2.2M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$3.48M
2
SLRN
ACELYRIN
SLRN
+$2.49M
3
AQST icon
Aquestive Therapeutics
AQST
+$2.13M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.3M
5
AXGN icon
Axogen
AXGN
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 86.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSVT
51
DELISTED
2seventy bio
TSVT
$1.26M 0.32%
429,252
-200,777
-32% -$824K
LCTX icon
52
Lineage Cell Therapeutics
LCTX
$282M
$1.26M 0.32%
2,511,374
+1,160,666
+86% +$852K
NGNE icon
53
Neurogene
NGNE
$710M
$1.18M 0.3%
51,500
+43,725
+562% +$1.63M
MDWD icon
54
MediWound
MDWD
$184M
$1.15M 0.29%
64,479
– –
ALGN icon
55
Align Technology
ALGN
$12.1B
$1.15M 0.29%
+5,500
New +$1.23M
BNTX icon
56
BioNTech
BNTX
$22.9B
$969K 0.25%
8,500
– –
GPCR icon
57
Structure Therapeutics
GPCR
$3.74B
$963K 0.24%
35,500
+1,500
+4% +$53.2K
SPRY icon
58
ARS Pharmaceuticals
SPRY
$551M
$937K 0.24%
88,790
-59,504
-40% -$833K
CMPS
59
Compass Pathways
CMPS
$1.83B
$919K 0.23%
243,210
– –
TSHA icon
60
Taysha Gene Therapies
TSHA
$1.82B
$904K 0.23%
+522,500
New +$1.08M
PYPD icon
61
PolyPid
PYPD
$92.2M
$885K 0.23%
291,273
-17,224
-6% -$56.6K
FHTX icon
62
Foghorn Therapeutics
FHTX
$327M
$881K 0.22%
186,717
+149,053
+396% +$1.09M
PVLA
63
Palvella Therapeutics
PVLA
$2.23B
$857K 0.22%
+71,452
New +$1.12M
STRO icon
64
Sutro Biopharma
STRO
$400M
$804K 0.2%
43,708
+10,750
+33% +$328K
CNTA
65
DELISTED
Centessa Pharmaceuticals
CNTA
$795K 0.2%
47,453
-72,898
-61% -$1.21M
VIR icon
66
Vir Biotechnology
VIR
$1.48B
$734K 0.19%
+100,000
New +$789K
CGEN icon
67
Compugen
CGEN
$218M
$684K 0.17%
447,202
– –
ACRV icon
68
Acrivon Therapeutics
ACRV
$72.3M
$677K 0.17%
112,414
– –
SAGE
69
DELISTED
Sage Therapeutics
SAGE
$588K 0.15%
108,200
– –
ACET icon
70
Adicet Bio
ACET
$74.1M
$577K 0.15%
37,500
– –
MASI
71
DELISTED
Masimo
MASI
$496K 0.13%
3,000
– –
AQST icon
72
Aquestive Therapeutics
AQST
$492M
$452K 0.11%
127,000
-462,561
-78% -$2.13M
APRE icon
73
Aprea Therapeutics
APRE
$7.83M
$451K 0.11%
137,174
– –
ADCT icon
74
ADC Therapeutics
ADCT
$144M
$446K 0.11%
224,081
+20,000
+10% +$52.3K
CATX icon
75
Perspective Therapeutics
CATX
$339M
$415K 0.11%
130,169
-100,153
-43% -$818K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, DAFNA Capital Management held 90 positions worth $393M, down 7.1% from $423M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $15.9M of net new capital in Q4 2024, opening 6 new positions and adding to 29 existing holdings. Its largest new stake was TELA Bio: 1,441,029 shares worth $4.35M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Viking Therapeutics, an estimated $3.48M trimmed.

  • DAFNA Capital Management's largest Q4 2024 buy was TELA Bio: 1,441,029 shares worth $4.35M.
  • DAFNA Capital Management added most to Revolution Medicines in Q4 2024, an estimated $5.71M increase.
  • DAFNA Capital Management's biggest Q4 2024 reduction was Viking Therapeutics, cutting an estimated $3.48M.
  • DAFNA Capital Management fully exited Nyxoah in Q4 2024, selling an estimated $1.03M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $393M portfolio in Q4 2024.
  • DAFNA Capital Management opened 6 new positions and closed 8 in Q4 2024.
  • DAFNA Capital Management's portfolio value fell 7.1% quarter-over-quarter to $393M.

Based on DAFNA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.